Before this is achieved, autoantibody against IGF2BP2 may potentially be used together with other biomarkers, such as p53, CEA, c-myc, and antinuclear antibody, in the diagnosis of colon cancer [22, 120]. Here, CEACAM5 is linked to colonic neoplasm.